| Fair Haven Of Forest City, Llc | |
| 830 Bethany Church Road, Forest City, North Carolina 28043 | |
| (828) 245-2852 | |
| Name | Fair Haven Of Forest City, Llc |
|---|---|
| Location | 830 Bethany Church Road, Forest City, North Carolina |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 100 |
| Occupancy Rate | 70% |
| Medicare ID (CCN) | 345314 |
| Legal Business Name | Fair Haven Of Forest City Llc |
| Ownership Type | For Profit - Partnership |
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
Scientists have solved a decade-old mystery that could eventually lead to the development of earlier treatments for one of the world's deadliest diseases, which affects up to 2 billion people.
Adamas Pharmaceuticals, Inc., a privately held company, announced today results from in vivo animal studies and in vitro tests demonstrating that its triple combination antiviral drug (TCAD) therapy is superior relative to double combinations and monotherapy against multiple strains of pandemic and avian influenza viruses. Results of these studies were presented Sunday evening in an oral session at the XII International Symposium on Respiratory Viral Infections being held in Taipei.
Deciphera Pharmaceuticals, a clinical stage biotechnology company focused on improved kinase inhibitor treatments for cancer, today announced the initiation of a Phase 1 clinical trial of its MET/TIE2/VEGFR2/TRK inhibitor altiratinib (DCC-2701).
At an exclusive event held at University of California, Irvine Applied Innovation Center, Lumitron Technologies, Inc. celebrated its arrival in the university's prestigious Research Park and introduced the gathered luminaries to the HyperVIEW system.
› Verified 6 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 1 |
| Total Amount of Fines in Dollars | $14060 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 1 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 20 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 12.68 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 70.97 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 1.02 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 1.08 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 1.72 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 1.29 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 100 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 9.48 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 100 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 0 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 36.31 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 43.18 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 0.86 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 88.79 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 87.45 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 95.69 | 82.93 |
News Archive
Scientists have solved a decade-old mystery that could eventually lead to the development of earlier treatments for one of the world's deadliest diseases, which affects up to 2 billion people.
Adamas Pharmaceuticals, Inc., a privately held company, announced today results from in vivo animal studies and in vitro tests demonstrating that its triple combination antiviral drug (TCAD) therapy is superior relative to double combinations and monotherapy against multiple strains of pandemic and avian influenza viruses. Results of these studies were presented Sunday evening in an oral session at the XII International Symposium on Respiratory Viral Infections being held in Taipei.
Deciphera Pharmaceuticals, a clinical stage biotechnology company focused on improved kinase inhibitor treatments for cancer, today announced the initiation of a Phase 1 clinical trial of its MET/TIE2/VEGFR2/TRK inhibitor altiratinib (DCC-2701).
At an exclusive event held at University of California, Irvine Applied Innovation Center, Lumitron Technologies, Inc. celebrated its arrival in the university's prestigious Research Park and introduced the gathered luminaries to the HyperVIEW system.
› Verified 6 days ago
Fair Haven Of Forest City, Llc Location: 830 Bethany Church Road, Forest City, North Carolina 28043 Phone: (828) 245-2852 |